Validation of Biomarkers for Prostate Cancer Prognosis
Technical Report,01 Sep 2014,29 Oct 2015
The University of Texas MD Anderson Cancer Center Houston United States
Pagination or Media Count:
The most significant challenge in managing localized prostate cancer is the decision of whether or not it needs to be treated. Nearly half of prostate cancers diagnosed in the U.S. fall into the low or very low risk category and have little likelihood of causing death. However, it is well known that a significant fraction of low risk cases are misclassified and actually have occult high-risk features or are destined to progress to high-risk disease. Therefore a critical need in localized prostate cancer is the development of biomarkers that predict occult or incipient aggressive disease in the low-risk population.